在西班牙,壮症患者对治疗属性的偏好
Carmen Fajardo1, Cristina Álvarez-Escola2, Betina Biagetti3
1Endocrinology Department, La Ribera University Hospital, Alzira, Valencia, Spain.
Endocrine
|July 28, 2023
概括
对于选择治疗方法的壮病患者来说,生活质量是最重要的优先事项. 共享决策至关重要,因为患者的偏好在很大程度上决定了这种罕见的生长激素疾病的治疗选择.
科学领域:
- 内分泌学 在内分泌学.
- 罕见疾病 罕见疾病
- 患者报告的结果
背景情况:
- 巨症是由多余的生长激素和类似胰岛素的生长因子I (IGF-I) 引起的.
- 巨症通过并发症显著影响患者的生活质量 (QoL).
- 治疗目标包括生化和瘤控制,但QoL的影响在历史上被忽视.
研究的目的:
- 探索患者对壮症治疗特征的偏好.
- 了解各种治疗因素在患者决策中的相对重要性.
主要方法:
- 采用面对面采访和离散选择实验 (DCE) 的横截面研究.
- 包括在治疗中至少一年的成年壮病患者.
- 从采访中提取患者对治疗属性的偏好.
主要成果:
- 改善生活质量是最有价值的治疗属性 (37%).
- 胰岛素样生长因子I (IGF-I) 控制 (20%),血糖控制 (17%) 和瘤控制 (13%) 也显著.
- 佩格维索曼 (Pegvisomant) 显示了最高的整体偏好份额,并且作为二线治疗非常受欢迎.
结论:
- 以患者为中心的护理是必不可少的,QoL是治疗偏好的主要驱动因素.
- 知情丰富的壮病患者应该积极参与治疗选择的共同决策.
相关概念视频
Adrenal Gland Disorders
1.6K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
1.6K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
201
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
201
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


